10-K: Astrotech Reports Wider Losses Amid Revenue Decline

Sentiment:

Annual Report 26 September 2025 8:07 AM

Astrotech Corporation reported a significant increase in net loss and a substantial decrease in revenue for fiscal year 2025, despite progress in product commercialization and new subsidiary launches.

Delay expectedCommercialization of the BreathTest-1000 is expected to require many years and significant investment due to regulatory requirements, leading to a decision to deploy capital to other subsidiaries instead.The governmental approval process for products like the BreathTest-1000 is described as lengthy, time-consuming, and inherently unpredictable, with no guarantee of timely approval or marketability.

Capital raiseThe company expects its short-term and long-term liquidity requirements to increase with business growth, R&D, and public company expenses.It anticipates needing to obtain additional funding in connection with continuing operations.Potential funding sources include equity offerings, debt financing, equity financing, merging, or engaging in a strategic partnership.The company explicitly states that if it is unable to raise capital when needed or on attractive terms, it would be forced to delay, reduce, or eliminate research and development programs or future commercialization efforts.

Worse than expectedNet loss increased to $13.850 million in fiscal year 2025 from $11.666 million in fiscal year 2024.Total revenue decreased by 37.0% to $1.049 million in fiscal year 2025 from $1.664 million in fiscal year 2024.Net cash used in operating activities increased to $12.952 million in fiscal year 2025 from $9.725 million in fiscal year 2024, indicating a higher cash burn.

Summary

Net loss for fiscal year 2025 increased to $13.850 million, up from $11.666 million in fiscal year 2024.
Total revenue decreased by 37.0% to $1.049 million in fiscal year 2025, down from $1.664 million in fiscal year 2024, primarily due to fewer TRACER 1000 units sold.
Operating expenses increased by 8.4% to $15.209 million, driven by a 19.9% increase in research and development expenses to $8.142 million.
Cash and cash equivalents decreased to $3.1 million at June 30, 2025, from $10.4 million at June 30, 2024, with net cash used in operating activities increasing to $12.952 million.
The company expects to need additional funding for ongoing operations, R&D, and business expansion, potentially through equity offerings, debt financing, or strategic partnerships.
Astrotech is commercializing its Astrotech Mass Spectrometer Technology (AMS Technology) and ATi Gas Chromatography Column (GC) platforms through wholly-owned subsidiaries: 1st Detect, AgLAB, BreathTech, Pro-Control, and EN-SCAN.
1st Detect's TRACER 1000 ETD received TSA approval for air cargo in June 2024 and advanced to Stage II testing, with the first TSA-approved sale of six units for $429,000 in April 2025.
AgLAB's 1000-D2 mass spectrometer is undergoing field trials, demonstrating over 20% improvement in THC/CBD oil yields during distillation.
BreathTech's BreathTest-1000 development for breath analysis is being de-prioritized due to lengthy regulatory requirements and significant investment needs, with capital reallocated to other subsidiaries.
New subsidiaries Pro-Control (industrial process control, formed Dec 2023) and EN-SCAN (environmental testing, formed Feb 2025) were launched to expand the application of AMS Technology.

Sentiment

Score: 3

Explanation: The company reported significantly increased net losses and a substantial decline in revenue, coupled with a higher cash burn from operations. While there are positive developments in product commercialization and new subsidiary launches, these are early-stage and have not yet translated into improved financial performance. The explicit need for future capital raises and the de-prioritization of a key product due to regulatory hurdles indicate significant financial and operational challenges.

Positives

1st Detect's TRACER 1000 ETD received TSA approval for air cargo in June 2024, advancing to Stage II field trials.
Secured a $429,000 purchase order and completed the first TSA-approved sale of six TRACER 1000 ETDs to Intuitive Research and Technology in April 2025.
Awarded a research and development contract with the U.S. Department of Homeland Security (DHS) for next-generation explosives trace detection in January 2025.
Launched the enhanced TRACER 1000 Narcotic Trace Detector (NTD) in March 2025, with its first international deployment in Vietnam in June 2025.
AgLAB's field trials for the AgLAB 1000-D2 demonstrated a significant improvement of 20% or more in ending-weight yields for cannabis and hemp oil distillation.
Successfully launched two new wholly-owned subsidiaries, Pro-Control, Inc. (December 2023) for industrial process control and EN-SCAN, Inc. (February 2025) for environmental testing, expanding the application of core technology.
Gross margin slightly increased to 45.3% in fiscal year 2025 from 45.1% in fiscal year 2024, indicating higher profitability on units sold.

Negatives

Net loss increased significantly to $13.850 million in fiscal year 2025 from $11.666 million in fiscal year 2024.
Total revenue decreased by 37.0% to $1.049 million in fiscal year 2025, primarily due to fewer TRACER 1000 units sold.
Net cash used in operating activities increased to $12.952 million in fiscal year 2025, indicating a higher cash burn rate.
Cash and cash equivalents decreased by $7.342 million to $3.1 million at June 30, 2025.
The company has an accumulated deficit of approximately $251 million as of June 30, 2025, and anticipates continued losses.
Commercialization of the BreathTest-1000 is being de-prioritized due to anticipated lengthy regulatory requirements and significant investment, with capital reallocated to other subsidiaries.
The company generates substantial revenue from a limited number of customers, posing a concentration risk.

Risks

Incurred significant losses since inception and anticipate continued losses for the foreseeable future, with uncertainty about achieving profitability.
Business units are in the development stage with limited revenues and uncertain future profitability, requiring substantial funding.
May need to raise additional capital, which could result in dilution to existing shareholders or impose significant restrictions through debt financing.
Challenges in obtaining and protecting intellectual property, and potential claims of infringement by third parties, leading to costly litigation or licensing expenses.
Failure to successfully develop new products, such as the BreathTest-1000, due to lengthy and unpredictable governmental approval processes (e.g., FDA).
Exposure to operational, financial, and regulatory risks in international markets, including tariffs, exchange rate fluctuations, political instability, and anti-corruption laws.
Adverse impact from inflation on cost structure, wages, supply chain inputs, and ability to meet customer demand.
Substantial revenue generation from a limited number of customers, making the company vulnerable to the loss of any such customer.
Dependence on third-party and single-source suppliers for critical components, leading to vulnerability to supply shortages, price fluctuations, and production delays.
Extensive governmental regulation of products and operations, particularly in the medical technology industry (FDA, state agencies), with non-compliance leading to severe enforcement actions.
The AgLAB business growth is highly dependent on the U.S. hemp and cannabis market, which faces risks from new regulations, licensing shortages, federal illegality (Controlled Substances Act), potential aiding and abetting claims, and opposition from other industries.
Stock price volatility and potential for rapid, substantial decreases, unrelated to operating performance, including risks from short squeezes.
Potential for dilution of shareholder interests from future sales of common or preferred stock without consulting existing shareholders.
Failure to maintain compliance with Nasdaq's continued listing requirements could result in delisting of common stock.
Increased cybersecurity requirements, vulnerabilities, and threats posing risks to systems, networks, products, services, and data.
Increased costs associated with corporate governance compliance, including Sarbanes-Oxley Act and Dodd-Frank Act regulations.
Inadequate insurance coverage for significant risk exposures.

Future Outlook

The company expects its expenses to increase with ongoing research and development and business expansion efforts. It anticipates needing additional funding to support these activities and public company costs. While the company believes its current cash and investments will cover operating expenses and capital expenditures for at least twelve months, it acknowledges the need for future capital raises through equity, debt, or strategic partnerships, which could lead to shareholder dilution or debt restrictions. The company does not anticipate inflation having a material impact on future results of operations.

Management Comments

Our mission encompasses the advancement of both mass spectrometry and gas chromatography, two powerful analytical techniques that together enable precise detection and identification of chemical compounds across a wide range of high-demand environments.
We aim to expand access to mass spectrometry by simplifying the complexity of operating these devices within real-time testing environments.
We believe that ETD customers are unsatisfied with the currently deployed ETD technology, which is driven by ion mobility spectrometry (IMS).
We further believe that some IMS-based ETDs have issues with false positives, as they often misidentify personal care products and other common household chemicals as explosives, causing facility shutdowns, unnecessary delays, frustration, and significant wasted security resources.
In contrast, adding additional compounds to the TRACER 1000s detection library does not degrade its detection capabilities, as it has a virtually unlimited and easily expandable threat library.
Management believes the AgLAB 1000-D2 will deliver a compelling combination of cost and time savings while enhancing product quality and quantity for distillation processors of hemp and cannabis.
Due in large part to our proprietary technology, we believe it is the only provider of a mass spectrometry system that gives it a distinct advantage in the industry.
We believe commercialization of BreathTech Corporation with the AMS Technology would require many years and significant investment due to regulatory requirements. As such, we have determined to deploy capital instead to our other subsidiaries.
We believe that our growth and future financial performance depend upon our ability to anticipate technological advances and customer requirements.

Industry Context

Astrotech operates in the specialized analytical instrumentation market, focusing on mass spectrometry and gas chromatography. Its 1st Detect subsidiary competes in the security and detection market, aiming to displace older ion mobility spectrometry (IMS) technology with its superior TRACER 1000. The AgLAB subsidiary targets the rapidly growing, but federally illegal and highly regulated, U.S. hemp and cannabis market, seeking to optimize distillation processes. The company's expansion into industrial process control (Pro-Control) and environmental testing (EN-SCAN) reflects a broader trend of applying advanced analytical techniques to real-time, on-site applications across diverse industries, driven by demand for faster, more accurate, and cost-effective solutions. The challenges faced by BreathTech highlight the significant regulatory hurdles and investment required for medical device commercialization, a common theme in the healthcare technology sector. The company's reliance on a few key customers and the competitive landscape with larger, established players are typical for smaller, innovative technology firms.

Comparison to Industry Standards

1st Detect's TRACER 1000 is positioned as superior to existing ion mobility spectrometry (IMS) based Explosive Trace Detectors (ETDs) used by competitors, citing near-zero false alarms, limitless library expansion, high uptime, and fast cleardown, which are critical performance metrics in airport and cargo security.
AgLAB's 1000-D2 mass spectrometer is presented as offering a more customer-friendly interface, quicker results, and closed-loop process control compared to High Performance Liquid Chromatography (HPLC) systems, which are the primary direct competition in the hemp and cannabis analysis market.
Pro-Control's AMS Technology aims to simplify mass spectrometry, enabling faster cycle times (minutes vs. hours or days) for on-site process adjustment, differentiating it from legacy, sophisticated MS equipment offered by global OEMs like ABB, Siemens, Emerson, Thermo Fisher Scientific, Endress and Hauser, Perkin Elmer, Mettler Toledo, PAC LP, Horiba Process Analyzers, and AMETEK, which are typically used for offline quality control in central analytical labs.
EN-SCAN differentiates its portable GC-MS devices from established environmental testing equipment providers through its proprietary ATi Gas Chromatograph and AMS Technology, rugged design for harsh field conditions, and emphasis on real-time, on-site analysis and cost efficiency.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Cybersecurity Oversight	Chief Financial Officer (CFO)	Chief Operating Officer (COO)	August 13, 2025	Internal policy review and ongoing turmoil at the Bureau of Industry and Security (BIS) led to a shift in direct supervision of the cybersecurity program from the CFO to the COO.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Rights Plan Extension	Amendment No. 2 to the Rights Agreement extended the Final Expiration Date of the stockholder rights plan to December 20, 2025.	December 12, 2024	Continues to provide anti-takeover protection by allowing existing stockholders to purchase common shares at half price if an 'Acquiring Person' (15% or more beneficial ownership) emerges, potentially delaying or deterring hostile acquisitions.
Bylaws Amendment	The Certificate of Incorporation and Bylaws provide the Board with the ability to alter Bylaws without stockholder approval, place limitations on director removal, and allow vacancies to be filled by a majority of directors in office.	N/A (existing provisions)	These provisions are expected to discourage coercive takeover practices and inadequate takeover bids, encouraging negotiation with the Board, but may also prevent stockholders from replacing management.
Blank Check Preferred Stock Authority	The Board is authorized to create and issue up to 2,500,000 shares of preferred stock in one or more series without stockholder approval, fixing their designations, powers, preferences, and rights.	N/A (existing authority)	This authority could be used to issue preferred stock that dilutes the interest or impairs the voting power of common stockholders, or as a method of deterring, delaying, or preventing a change of control.
Advance Notice Bylaws	Bylaws contain an advance notice procedure for stockholder proposals and nominations for Board election at meetings.	N/A (existing provisions)	May preclude certain business from being conducted if proper procedures are not followed, or discourage potential acquirers from proxy solicitations to gain control.
Delaware Forum Selection Clause	Certificate of Incorporation designates the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain disputes between the company and its stockholders.	N/A (existing provision)	Could limit stockholders' ability to obtain a favorable judicial forum for disputes, potentially discouraging lawsuits, especially for stockholders not residing in or near Delaware.

Legal Proceedings

The company is subject to legal and administrative proceedings, settlements, investigations, claims, and actions from time to time.
Management does not believe any current matters, individually or in aggregate, will have a material adverse effect on the company's financial position or results of operations.

Stakeholder Impact

**Shareholders**: Face significant dilution risk from potential future equity capital raises, continued losses, and stock price volatility. The anti-takeover provisions and preferred stock authority may limit their influence on corporate control. The Delaware forum selection clause may increase litigation costs.
**Employees**: The company's ongoing success is dependent on retaining key employees and attracting new talent in a competitive market. Stock-based compensation is a component of their remuneration.
**Customers**: Benefit from new product introductions (TRACER 1000 NTD, AgLAB 1000-D2, Pro-Control 1000-D2, EN-SCAN lineup) offering improved detection, yield optimization, and real-time analysis. However, the company's revenue concentration on a limited number of customers indicates high dependence on these relationships.
**Suppliers**: The company's manufacturing operations are highly dependent on third-party and single-source suppliers, making them critical partners. Supply chain disruptions or changes in demand could impact these relationships.
**Regulatory Bodies**: The company is subject to extensive and complex regulations (SEC, FDA, TSA, DHS, ECAC, state cannabis laws, data privacy laws), requiring significant compliance efforts and posing risks of enforcement actions if not met.

Next Steps

Conduct field trials for the TRACER 1000 ETD with the TSA to advance to the 'qualified' list.
Complete Developmental Test and Evaluation for TSA checkpoint testing of the TRACER 1000.
Continue sales efforts for the AgLAB 1000-D2, including engaging additional channel partners.
Continue development of the AgLAB-1000-D1 as an inline process control unit for distillation equipment.
Refine Pro-Control's product line and develop its library for chemical manufacturers.
Continue R&D efforts for EN-SCAN's new line of environmental testing instruments.
Relocate to the new Metric facility in Austin, Texas, during fiscal year 2026.
Obtain additional funding through equity offerings, debt financing, or strategic partnerships to support ongoing operations and expansion.

Key Dates

Date	Description
March 24, 2021	Effective date of the initial Letter of Agreement with Sanmina Corporation for manufacturing and supply of products.
March 31, 2021	Effective date of the Investigator-Initiated Study Agreement (CCF IISA) with The Cleveland Clinic Foundation for BreathTech's breath analysis tool.
April 27, 2021	Company entered into a lease for a research and development facility in Austin, Texas.
September 22, 2021	Effective date of Amendment No. 1 to the Letter of Agreement with Sanmina, extending its term.
December 1, 2021	Effective date of Amendment No. 2 to the Letter of Agreement with Sanmina, further extending its term.
October 12, 2022	Effective date of Amendment No. 3 to the Letter of Agreement with Sanmina, further extending its term.
November 9, 2022	Board of Directors authorized a share repurchase program of up to $1.0 million of common stock.
November 11, 2022	Company signed a lease extension agreement for the R&D facility, extending the term through April 30, 2025.
November 22, 2022	Astrotech entered into a sublease agreement for an additional facility adjacent to the R&D facility.
December 1, 2022	Commencement date of the sublease for the additional facility.
December 21, 2022	Company entered into a Rights Agreement with American Stock Transfer & Trust Company, LLC, and the Board declared a dividend of one Preferred Share purchase right for each common stock share outstanding.
January 5, 2023	Record Date for the Preferred Share purchase rights dividend.
June 16, 2023	Company terminated the share repurchase program.
December 12, 2023	Company announced the formation of its new wholly-owned subsidiary, Pro-Control, Inc.
December 18, 2023	Company entered into Amendment No. 1 to Rights Agreement, extending the Final Expiration Date to December 20, 2024.
June 13, 2024	AgLAB and SC Laboratories entered into a master lease agreement for joint marketing of the AgLAB 1000-D2.
June 2024	TSA approved 1st Detect's TRACER 1000 for the Air Cargo Security Technology List, advancing it to Stage II testing.
December 12, 2024	Company entered into Amendment No. 2 to Rights Agreement, extending the Final Expiration Date to December 20, 2025.
January 8, 2025	1st Detect Corporation was awarded a research and development contract with the U.S. Department of Homeland Security (DHS).
January 14, 2025	1st Detect Corporation announced the award of research and development contract 70RSAT24CB0000015 with the U.S. Department of Homeland Security (DHS).
January 20, 2025	Company entered into a lease extension for the Donley Facilities, effective May 1, 2025.
January 24, 2025	Company fulfilled a $429,000 purchase order and sold six TRACER 1000 ETDs to Intuitive Research and Technology, marking the first TSA-approved sale.
January 29, 2025	Company entered into a new lease agreement for the Metric facility in Austin, Texas.
February 7, 2025	The pilot study with Cleveland Clinic Foundation for BreathTech's BreathTest-1000 concluded and the CCF IISA terminated.
February 28, 2025	Astrotech Corporation announced the formation of its new wholly-owned subsidiary, EN-SCAN, Inc.
March 10, 2025	Astrotech Corporation announced the launch of its enhanced TRACER 1000 Narcotic Trace Detector (NTD).
April 2025	Astrotech received a $429,000 purchase order for TRACER 1000 ETDs from Intuitive Research and Technology.
April 2025	Company fulfilled the purchase order and sold six TRACER 1000 explosive detectors to Intuitive Research and Technology Corporation.
May 1, 2025	Effective date of the month-to-month lease extension for the Donley Facilities.
June 12, 2025	1st Detect Corporation sold and deployed its first TRACER 1000 Narcotic Trace Detector in Vietnam.
June 30, 2025	End of the fiscal year for this annual report.
July 1, 2025	Commencement date of the lease for the new Metric facility in Austin, Texas.
July 1, 2025	Effective date of the Fourth Amendment to Letter of Agreement with Sanmina, extending the agreement and adding inventory management terms.
July 10, 2025	All mentions of TRACER 1000 or 1st Detect and its products were removed from infringing companies' websites following demand letters.
July 25, 2025	Date of signature for Sanmina Corporation on the Fourth Amendment to Letter of Agreement.
July 26, 2025	Date of signature for Astrotech Technologies, Inc. on the Fourth Amendment to Letter of Agreement.
July 28, 2025	U.S. announced a preliminary trade deal with the European Union, setting a 15% tariff on most EU goods.
August 12, 2025	Chief Financial Officer's direct supervision of cybersecurity program ends.
August 13, 2025	Chief Operating Officer's direct supervision of cybersecurity program begins.
September 24, 2025	Date for which authorized and outstanding capital stock figures are provided.
September 26, 2025	Date of the audit report and filing of the Annual Report on Form 10-K.
December 20, 2025	Extended Final Expiration Date of the Rights Plan.
February 11, 2026	Expiration date for 5,689 warrants issued on February 16, 2021.
April 7, 2026	Expiration date for 49,770 warrants issued on April 12, 2021.
November 2032	Expiration of lease for the manufacturing property in Austin, Texas.

Recommendation

sell

The company's financial performance is deteriorating, marked by a significant increase in net losses and a substantial decline in revenue. Cash burn from operations has increased, and the company explicitly states the need for additional capital, which will likely result in further shareholder dilution. While there are positive developments in product commercialization and new business unit formation, these are early-stage and have not yet translated into profitability. The de-prioritization of the BreathTech product due to regulatory hurdles highlights execution risks. The stock price has been volatile, and the underlying financial metrics suggest a disconnect between market valuation and operational reality. Given the sustained losses, increased cash burn, and the need for future capital, a seasoned investor would likely recommend selling to mitigate further downside risk.

Keywords

Mass Spectrometry, Gas Chromatography, Explosive Trace Detectors, Narcotic Trace Detectors, TRACER 1000, AgLAB 1000-D2, Hemp and Cannabis Industry, Industrial Process Control, Environmental Testing, SEC Filing, 10-K, Astrotech Corporation, ASTC, TSA Approval, ECAC Certification, R&D, Financial Performance, Liquidity, Capital Raise

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.